New Drug Doubles Pancreatic Cancer Survival in Late-Stage Trial
Revolution Medicines’ drug, daraxonrasib, has demonstrated “dramatic, practice-changing outcomes” in a pivotal Phase 3 trial for pancreatic cancer, nearly doubling typical survival length and significantly reducing the risk of death compared to chemotherapy. The daily pill met all primary and secondary endpoints, offering patients a median survival of 13.2 months, a substantial increase from the 6.7 months seen with chemotherapy. These “unprecedented” results target RAS mutations common in pancreatic cancer and are expected to usher in a new era of RAS-targeted treatments. The company plans to seek expedited FDA approval for this potentially transformative therapy.
John Q. Hosedrinker